

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)



(10) International Publication Number
WO 2021/260394 A1

(51) International Patent Classification:
C07K 14/47 (2006.01) C12N 7/00 (2006.01)

(21) International Application Number:
PCT/GB2021/051627

(22) International Filing Date:
25 June 2021 (25.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2009741.6 25 June 2020 (25.06.2020) GB

(71) Applicant: **FREELINE THERAPEUTICS LIMITED**
[GB/GB]; Stevenage Bioscience Catalyst, Gunnels Wood
Road, Stevenage Hertfordshire SG1 2FX (GB).

(72) Inventors: **KIA, Azadeh**; c/o Freeline Therapeutics
Limited, Stevenage Bioscience Catalyst, Gunnels Wood
Road, Stevenage Hertfordshire SG1 2FX (GB). **FOLEY,
Jonathan**; c/o Freeline Therapeutics Limited, Stevenage
Bioscience Catalyst, Gunnels Wood Road, Stevenage Hert-
fordshire SG1 2FX (GB). **CANAVESE, Miriam**; c/o Free-
line Therapeutics Limited, Stevenage Bioscience Cata-
lyst, Gunnels Wood Road, Stevenage Hertfordshire SG1
2FX (GB). **CORBAU, Romuald**; c/o Freeline Thera-
peutics Limited, Stevenage Bioscience Catalyst, Gunnels
Wood Road, Stevenage Hertfordshire SG1 2FX (GB).
CORREIA, Samantha; c/o Freeline Therapeutics Limit-
ed, Stevenage Bioscience Catalyst, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2FX (GB).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London
EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: POLYNUCLEOTIDE

(57) Abstract: The present invention relates to a polynucleotide comprising a Complement Factor I (CFI) nucleotide sequence encoding a CFI polypeptide or a fragment thereof. The invention further relates to a viral particle comprising a recombinant genome comprising the polynucleotide of the invention, and a composition comprising the polynucleotide or viral particle of the invention. The invention also relates to methods of using, and uses of, the polynucleotide, viral particle and/or composition of the invention. The invention also relates to methods of using, and uses of, a polynucleotide comprising a CFI nucleotide sequence, a viral particle comprising a recombinant genome comprising the polynucleotide, or a composition comprising the polynucleotide or viral particle.

WO 2021/260394 A1